Company Information

  

Address: PAASHEUVELWEG 25A  
City: AMSTERDAM 
State:  
Zip Code: 1105 BP 
Telephone: 1-339-970-7000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a leader in the field of gene therapy, seeking to develop single treatments with potentially curative results for patients suffering from genetic and other devastating diseases. We are advancing a focused pipeline of innovative gene therapies that have been developed both internally and through our collaboration, focused on cardiovascular diseases, with Bristol Myers-Squibb ("BMS"). We have established clinical proof-of-concept in our lead indication, hemophilia B, and achieved preclinical proof-of-concept in Huntington's disease. We believe our validated adeno-associated virus ("AAV") technology platform and proprietary insect cell-based manufacturing capabilities provide us distinct competitive advantages, including the potential to reduce development risk, cost and time to market.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-2.73NAN/E
12/2017-2.94NAN/E
09/2017-2.61NAN/E
06/2017-2.82NAN/E
03/2017-2.83NAN/E
12/2016-2.93NAN/E
12/2015-3.24NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.14Total Liab/Total Assets0.57
Net Inc/Total Assets-0.38Total Liab/Inv Cap0.64
Net Inc/Inv Cap-0.42Total Liab/Comm Equity0.21
Pretax Inc/Net Sales-6.06Interest Coverage Ratio-34.60
Net Inc/Net Sales-6.05Curr Debt/Equity0.01
Cash Flow/Net Sales-4.90LTD/Equity0.24
SG&A/NetSales0.94Total Debt/Equity0.25
Asset Utilization   Liquidity  
Net Receivables Turnover2.43Quick Ratio8.47
Inventory TurnoverNACurrent Ratio8.47
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.09Inv/Curr AssetsNA
Net Sales/PP&E0.38  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 3.48 2.58 2.26 4.94
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 6.02 7.02 -8.57 7.78
Operating Income -19.60 -22.65 -9.28 -19.71
Interest Exp 0.42 0.65 0.58 0.50
Pretax Income -18.88 -27.40 -10.52 -21.27
Other Income 1.13 -4.10 -0.67 -1.06
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -18.79 -27.47 -10.25 -21.27

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 140.82 159.37 88.93 104.09
Receivables - Total 1.06 1.59 1.95 5.82
Inventories - Total NA NA NA NA
Total Current Assets 145.47 162.78 92.32 111.43
Net Property, Plant & Equipment 33.84 34.28 34.65 35.41
Total Assets 192.24 209.64 138.99 157.97
Liabilities        
Accounts Payable 10.19 11.75 13.15 12.90
Debt in Current Liabilities 4.44 1.05 6.23 4.32
Total Current Liabilities 26.56 19.23 25.37 23.13
Long-Term Debt 16.87 21.04 14.35 16.15
Total Liabilities 91.98 120.29 119.38 130.68
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 1.97 1.95 1.61 1.61
Retained Earnings -470.99 -475.32 -447.84 -437.60
Treasury Stock NA NA NA NA
Total Stockholders' Equity 100.26 89.36 19.61 27.29
Total Liabilities and Stockholders' Equity 192.24 209.64 138.99 157.97

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -21.44 -18.05 -15.42 -19.14
Net Cash Provided by Investing Activities -0.65 -0.65 -1.53 -1.44
Net Cash Provided by Financing Activities 1.56 89.04 0.10 0.50

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20134.06-36.96--
12/20146.14-49.78--
12/201510.58-82.08-3.24
12/201625.10-73.37-2.93
12/201713.11-79.26-2.94
Growth Rates34.08----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/188516,44645.34




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.